On this page
Congenital lipodystrophy type 1
This condition leads to various metabolic complications, including severe insulin resistance, high blood sugar, and elevated triglycerides. Understanding its genetic basis is key for diagnosis and managing its impact on health.
Available at Jeen Health
Clinical tests that include this
Overview
Congenital lipodystrophy type 1, also known as Berardinelli-Seip congenital lipodystrophy type 1 (BSCL1), is a rare inherited condition present from birth. It is characterised by a significant reduction or complete absence of body fat, particularly under the skin, in deeper tissues, and within organs [PMID:16331899]. This widespread lack of adipose tissue, which normally stores energy and produces hormones, leads to a range of complex metabolic problems affecting how the body uses energy.
Individuals born with this condition typically have a distinctive appearance due to the absence of subcutaneous fat, including prominent musculature and a characteristic facial structure. While the condition affects individuals from birth, metabolic complications often become more pronounced during childhood and adolescence. Careful medical management is essential to address the various health challenges associated with congenital lipodystrophy type 1.
Symptoms & clinical features
The primary clinical feature of congenital lipodystrophy type 1 is the near-complete lack of body fat from birth. This results in highly muscular limbs and a generally lean, athletic build, even in infancy. Veins may appear very prominent under the skin due to the absence of insulating fat [PMID:16331899]. Affected individuals often have enlarged hands and feet, and their bones may appear more prominent.
Metabolic complications are a significant aspect of the condition. These can include severe insulin resistance, where the body's cells do not respond effectively to insulin, leading to high blood sugar levels (hyperglycaemia) [PMID:33679883]. Other common features are high levels of triglycerides (hypertriglyceridaemia), an enlarged liver and spleen (hepatosplenomegaly), and acanthosis nigricans, which causes dark, thickened skin patches, especially in body folds. Some individuals may also experience cardiomyopathy (heart muscle disease) or kidney problems.
Video: Genetics 101
Affected organs
Congenital lipodystrophy type 1 affects multiple organ systems, often as a consequence of the underlying metabolic dysregulation. The absence of adipose tissue directly impacts metabolic organs, particularly the liver and pancreas.
The liver can become enlarged and accumulate fat (hepatic steatosis) due to the body's inability to properly store lipids in fat cells. The pancreas may also be affected, leading to its dysfunction and contributing to insulin resistance and diabetes. The heart can be impacted, with some individuals developing cardiomyopathy. Additionally, the condition can affect the kidneys, potentially leading to renal problems over time, and the skin, causing characteristic darkened and thickened areas.
Risks & severity
Congenital lipodystrophy type 1 presents with a wide spectrum of severity, though it is generally considered a severe condition from birth. The absence of fat tissue is uniformly present, but the degree and onset of metabolic complications can vary. Untreated, severe insulin resistance can progress to type 2 diabetes mellitus, often in early childhood or adolescence [PMID:33679883].
High triglyceride levels can lead to a risk of pancreatitis, a painful inflammation of the pancreas. Liver dysfunction, including fatty liver, can also progress. While rare, cardiomyopathy and kidney disease can pose significant long-term risks. The exact prevalence of congenital lipodystrophy type 1 is not well established due to its rarity. Lifespan can be shortened by severe metabolic complications, but with appropriate medical management, individuals can live well into adulthood.
Genetic causes
Congenital lipodystrophy type 1 is caused by pathogenic variants in the AGPAT2 gene. This gene provides instructions for making an enzyme called 1-acylglycerol-3-phosphate O-acyltransferase 2. This enzyme plays a critical role in the synthesis of both phospholipids and triglycerides, which are essential types of lipid molecules.
Phospholipids are a main component of cell membranes, while triglycerides are the primary way the body stores fat for energy. The AGPAT2 enzyme is particularly important for the development and proper function of adipose (fat) tissue [PMID:16331899]. When pathogenic variants occur in AGPAT2, the enzyme's function is impaired, disrupting normal lipid synthesis and leading to the inability to form and maintain healthy fat cells. This results in the characteristic near-complete absence of body fat seen in individuals with congenital lipodystrophy type 1.
- AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2The AGPAT2 gene encodes an enzyme crucial for the synthesis of specific fats, playing a vital role in the growth and function of fat-storing cells (adipocytes).
Inheritance pattern
Congenital lipodystrophy type 1 is inherited in an autosomal recessive pattern. This means that a person must inherit two altered copies of the AGPAT2 gene - one from each parent - to develop the condition. Individuals who inherit only one altered copy of the gene are known as carriers.
Carriers typically do not show any symptoms of congenital lipodystrophy type 1 themselves because their one working copy of the gene is sufficient to produce enough of the necessary enzyme. If two carriers have children together, there is a 25% chance with each pregnancy that their child will inherit two altered gene copies and therefore develop the condition, a 50% chance the child will be a carrier, and a 25% chance the child will inherit two working copies and not be affected or a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of congenital lipodystrophy type 1 typically begins with clinical observation of the characteristic physical features, such as the near-complete absence of body fat, prominent musculature, and metabolic abnormalities. Blood tests will often reveal high blood sugar, elevated insulin levels, and high triglyceride levels. Imaging studies, such as MRI or DEXA scans, can confirm the loss of adipose tissue.
Confirmation of the diagnosis is made through genetic testing, which looks for pathogenic variants in the AGPAT2 gene. In the UK, genetic testing for lipodystrophy syndromes, including congenital lipodystrophy type 1, is available through the NHS Genomic Medicine Service. This typically involves a referral to a clinical genetics service by a specialist clinician, such as an endocrinologist or paediatrician. Relevant R-codes for genetic testing may include those for inherited metabolic disorders or specific lipodystrophy panels.
Management & lifestyle
While there is currently no cure for congenital lipodystrophy type 1, management focuses on addressing the metabolic complications and improving the quality of life for affected individuals. This generally involves a multi-disciplinary team approach within the NHS, including endocrinologists, dietitians, and other specialists as needed. Close monitoring of blood sugar levels, lipid profiles, and liver function is crucial.
Dietary modifications, often involving a low-fat, high-carbohydrate diet with careful management of sugar intake, are usually recommended. Medications to manage blood glucose levels, such as insulin or other antidiabetic drugs, and to lower triglycerides may be prescribed. In some cases, specific hormone therapies may be considered to help manage metabolic control. Regular follow-up appointments with specialists are essential to adjust treatments as needed and to monitor for potential complications. Genetic counselling is also an important part of the management pathway, providing information and support to individuals and families regarding the condition's inheritance and implications.
UK care pathway
In the UK, individuals suspected of having congenital lipodystrophy type 1 would typically be referred to a specialist centre, often within paediatric or adult endocrinology, or clinical genetics services. The NHS Genomic Medicine Service provides comprehensive genomic testing and diagnosis pathways. Genetic testing, when appropriate, is facilitated through the Genomic Laboratory Networks, with specific R-codes used to ensure the correct tests are performed. Following diagnosis, individuals and their families should have access to genetic counsellors who can provide detailed information about the condition, its inheritance pattern, and support networks. Care is usually coordinated by a multidisciplinary team.
Frequently asked questions
What is the typical life expectancy for someone with congenital lipodystrophy type 1?
With careful medical management and consistent monitoring of metabolic complications, individuals with congenital lipodystrophy type 1 can live into adulthood. However, severe complications like heart disease or pancreatitis can impact life expectancy if not effectively managed.
Can congenital lipodystrophy type 1 be prevented?
Congenital lipodystrophy type 1 is a genetic condition caused by inherited gene changes, so it cannot be prevented. For families with a known history, genetic counselling can provide information about the risks to future children and available reproductive options.
Are there any specific dietary recommendations for this condition?
Yes, dietary management is a cornerstone of treatment. Generally, a diet low in fat and carefully controlled for carbohydrates and sugars is recommended. A specialist dietitian, often part of an NHS multidisciplinary team, can provide personalised advice to manage metabolic complications.
What is insulin resistance, and how does it relate to this condition?
Insulin resistance is a condition where the body's cells do not respond effectively to insulin, a hormone that helps regulate blood sugar. In congenital lipodystrophy type 1, the lack of fat tissue means there are fewer places for the body to store excess energy, leading to abnormal insulin signalling and dangerously high blood sugar levels.
Will having congenital lipodystrophy type 1 affect my children?
Congenital lipodystrophy type 1 is inherited in an autosomal recessive manner. If you have the condition, all of your children will inherit one altered copy of the AGPAT2 gene from you. Whether they develop the condition depends on the gene copy they inherit from their other parent. Genetic counselling can provide detailed, personalised risk assessments.